Alto Neuroscience, Inc. (ANRO)

14.60 +0.72 (+5.19%) 收市：04:00PM EDT

Alto Neuroscience, Inc.

369 South San Antonio Road
Los Altos, CA 94022
United States
650 200 0412
https://www.altoneuroscience.com

版塊: Healthcare
行業: Biotechnology
全職員工: 

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Amit Etkin M.D., Ph.D.	Founder, Chairman of the Board, CEO & President	705.65k	無	1977
Mr. Nicholas C. Smith	CFO & Secretary	624.12k	無	1989
Mr. Adam Savitz M.D., Ph.D.	Chief Medical Officer	579.57k	無	1966
Ms. Melissa Berman	Vice President of Finance & Accounting	無	無	1980
Ms. Erin R. McQuade J.D.	General Counsel & Chief Administrative Officer	無	無	1975
Ms. Jessica Powell	Chief Development Officer	無	無	1975
Mr. Fadi Abdel M.D.	Senior Vice President of Innovation	無	無	1979

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

公司管治

截至 無 止，Alto Neuroscience, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。